JINLING PHARM.(SZ:000919)2022-08-22 16:00Share Capital and Dividends - Jinling Pharmaceutical's total shares increased from 504 million to 510.4 million after the completion of the restricted stock incentive plan in February 2022[22]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[4]. - The company has not distributed cash dividends or bonus shares for the half-year period[78]. - The company completed the grant registration of 6.4 million restricted stocks to 72 incentive objects at a grant price of 3.69 CNY per share[82]. - The company received approval from the Nanjing State-owned Assets Supervision and Administration Commission for its 2021 restricted stock incentive plan[81]. - The company issued 6.4 million A-shares at a price of 3.69 RMB per share on January 17, 2022, with the shares listed on February 16, 2022[130]. - A total of 72 incentive recipients were granted 6.4 million restricted shares under the 2021 Restricted Stock Incentive Plan, with the grant date set on January 27, 2022[132]. Financial Performance - The company's total revenue for the reporting period was CNY 1,352,179,184.74, a decrease of 4.92% compared to the same period last year[23]. - Net profit attributable to shareholders was CNY 59,211,354.27, down 22.05% year-over-year[23]. - The net cash flow from operating activities was CNY 413,347.66, a significant decline of 99.75% compared to the previous year[23]. - Basic and diluted earnings per share were both CNY 0.1165, reflecting a decrease of 22.69% from the prior year[23]. - The company's total operating revenue for the reporting period was ¥1,352,179,184.74, representing a decrease of 4.92% compared to ¥1,422,221,213.81 in the same period last year[46]. - The total profit for the first half of 2022 was CNY 83,347,790.98, a decline of 31.4% from CNY 121,495,799.91 in the previous year[156]. - The company reported a net profit margin of approximately 6.5% for the first half of 2022, down from 8.9% in the same period of 2021[155]. - The company achieved a net profit of CNY 68,180,188.34, a decrease of 27.5% compared to CNY 93,889,092.81 in the first half of 2021[156]. Assets and Liabilities - The company's total assets increased by 1.27% to CNY 4,503,977,145.82 compared to the end of the previous year[23]. - The net assets attributable to shareholders rose by 1.57% to CNY 2,973,678,574.37[23]. - Cash and cash equivalents decreased to ¥1,078,057,736.57, accounting for 23.94% of total assets, down 9.83% from the previous year due to subsidiary investments[52]. - Accounts receivable increased to ¥387,359,636.38, representing 8.60% of total assets, up 1.39% from the previous year[52]. - Total liabilities decreased to CNY 887,027,567.38 from CNY 913,096,006.32, indicating a reduction of about 2.9%[150]. - The total assets at the end of the reporting period amounted to 510.4 million yuan, with total liabilities of 483.4 million yuan[176]. Research and Development - The company invested CNY 20.0975 million in research and development during the reporting period[41]. - Research and development expenses amounted to ¥20,097,465.06, down 11.49% from ¥22,707,636.56 in the previous year[46]. - The company is cautious about R&D risks associated with new drug development and is optimizing its R&D strategy[73]. - The R&D expenses for the period were 380 million, accounting for approximately 11.6% of total revenue[168]. - Research and development expenses for the first half of 2022 were 2.9 million yuan, which is a 4.3% increase from the previous year[169]. Market Position and Strategy - The company maintained its focus on pharmaceutical manufacturing and healthcare services, with key products including Suplife and Pilex[32][33]. - The company is positioned in a strategic industry that is crucial for national health and economic development, with a strong reputation in the pharmaceutical sector[35]. - The company plans to focus on expanding its market presence and investing in new product development in the upcoming quarters[155]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[167]. - The company is exploring potential acquisitions to enhance its product portfolio and market position[167]. Risk Management - The report emphasizes the importance of risk awareness regarding industry policy changes and market competition risks[3]. - The company is committed to risk management, implementing a dual prevention mechanism for risk control[39]. - The company is facing risks from industry policy changes, including drug approval and price control measures, and plans to adapt its business model accordingly[70]. Environmental and Social Responsibility - The company is focusing on improving its environmental management systems to comply with stricter regulations in the pharmaceutical industry[72]. - The company has implemented two wastewater treatment facilities with capacities of 1200 m³/d and 800 m³/d, ensuring that treated wastewater meets discharge standards[85]. - The company’s environmental monitoring results indicate that all pollutants are discharged within the standards[88]. - The company organized 178 personnel to assist in COVID-19 testing, completing 1.1 million tests across various cities[38]. - The company actively supports rural revitalization projects, achieving sales revenue of 330,000 CNY and a profit of 130,000 CNY from the honeysuckle tea project from January to June 2022[92]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the chairman and accounting heads[3]. - The report indicates that all board members attended the meeting to review the report, ensuring collective responsibility for its contents[3]. - The company has revised its articles of association and related governance rules as part of its corporate governance improvements[119]. - The company follows the accounting standards set by the Ministry of Finance, ensuring that its financial statements reflect its financial position accurately[193]. Legal and Compliance - The company is currently involved in a lawsuit seeking 1,772.32 million RMB related to a share transfer dispute, which is still under review[102]. - The company has not reported any major litigation or arbitration matters during the reporting period[102]. - There are no violations regarding external guarantees reported during the period[99]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[90].